Sugi Predict

Sugi Predict / Targets / NCOA1

NCOA1

Nuclear receptor coactivator 1 · Q15788 · NCOA1 on Sugi Atlas →

69,480 patent compounds predicted against NCOA1, 48,394 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL204872 SCHEMBL204872 0.47 4/20
Iodide Iodide (SCHEMBL124471) 1.00 3/20
Iodide Iodide (SCHEMBL124472) 1.00 3/20
Iodide Iodide (SCHEMBL145145) 0.60 3/20
Iodide Iodide (SCHEMBL145146) 0.60 3/20
SCHEMBL206078 SCHEMBL206078 0.52 3/20
Pyridaben Pyridaben (SCHEMBL27429) 0.40 3/20
Methylene Blue Cation Methylene Blue Cation (SCHEMBL127316) 1.00 2/20
SCHEMBL140322 SCHEMBL140322 0.84 2/20
Triapine Triapine (SCHEMBL29370) 0.68 2/20
Triapine Triapine (SCHEMBL29371) 0.68 2/20
SCHEMBL129194 SCHEMBL129194 0.66 2/20
SCHEMBL25640 SCHEMBL25640 0.65 2/20
SCHEMBL244059 SCHEMBL244059 0.63 2/20
SCHEMBL70702 SCHEMBL70702 0.56 2/20
SCHEMBL129213 SCHEMBL129213 0.56 2/20
SCHEMBL38924 SCHEMBL38924 0.56 2/20
SCHEMBL217044 SCHEMBL217044 0.55 2/20
SCHEMBL195208 SCHEMBL195208 0.52 2/20
SCHEMBL140214 SCHEMBL140214 0.51 2/20

Clinical trials — most relevant to NCOA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Chronic Effects of Estrogen in Microcirculation PHASE4COMPLETED
Fulvestrant in Metastatic Breast Cancer PHASE4UNKNOWN
Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword? PHASE4UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room PHASE2/PHASE3COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer PHASE1/PHASE2RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
AR-inhibitor Bicalutamide in Treating Patients With TNBC PHASE2UNKNOWN
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer PHASE2RECRUITING
Fibrates in Pediatric Cholestasis PHASE2COMPLETED
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer PHASE2COMPLETED
Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer nanACTIVE_NOT_RECRUITING
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer nanUNKNOWN
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B. nanUNKNOWN
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women nanCOMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy nanCOMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Precision High-Intensity Training Through Epigenetics (PHITE) nanCOMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Purinergic Signaling and the Postmenopausal Heart nanRECRUITING
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT nanCOMPLETED
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone. nanCOMPLETED
Tecfidera Diffusion Tensor Imaging nanCOMPLETED
Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects nanUNKNOWN
Molecular Pathways Related to Short-term Fasting Response nanCOMPLETED
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NCOA1 binder may also engage these)

ProteinNameSimilarity
P70365 — 1.000 P70365 →
Q4PJW2 — 1.000 Q4PJW2 →
O09000 — 0.998 O09000 →
NCOA2 Nuclear receptor coactivator 2 (NCoA-2) (Clas 0.995 landscape →
Q9WUI9 — 0.994 Q9WUI9 →
B5DE09 — 0.993 B5DE09 →
Q98TW1 — 0.992 Q98TW1 →
O57539 — 0.991 O57539 →
Q61026 — 0.991 Q61026 →
Q9W705 — 0.990 Q9W705 →
NCOA3 Nuclear receptor coactivator 3 0.989 landscape →
Q03297 — 0.988 Q03297 →
Q5R8Q4 — 0.987 Q5R8Q4 →
Q9HAU0 — 0.987 Q9HAU0 →
Q62415 — 0.987 Q62415 →
O70546 — 0.986 O70546 →
Q96KQ4 — 0.986 Q96KQ4 →
Q09YG9 — 0.986 Q09YG9 →
Q5XJV7 — 0.985 Q5XJV7 →
Q24767 — 0.985 Q24767 →
Q9H694 — 0.985 Q9H694 →
Q25637 — 0.984 Q25637 →
Q8VHG2 — 0.984 Q8VHG2 →
Q8R205 — 0.984 Q8R205 →
Q66IV1 — 0.984 Q66IV1 →
Q07E15 — 0.984 Q07E15 →
Q9EST3 — 0.984 Q9EST3 →
PTPN14 Tyrosine-protein phosphatase non-receptor type 14 0.984 landscape →
Q9NRA8 — 0.984 Q9NRA8 →
P15336 — 0.984 P15336 →